A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

NCT04272203 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Acute Myeloid Leukemia (AML)
Non Small Cell Lung Cancer
Cancer

Interventions

DRUG: ABBV-184

Sponsor

AbbVie